Coulaud P.-J., Sagaon-Teyssier L., Mimi M., M’madi Mrenda B., Maradan G., Mora M., Bourrelly M., Keita B. D., Keita A. A., Anoma C., Babo Yoro S.-A., Dah T. T. E., Coulibaly C., Mensah E., Agbomadji S., Bernier A., Couderc C., Laurent C., Spire B., et CohMSM Study Group,
Combined Sexual Behavioral Profiles in HIV-Seronegative Men Who have Sex with Men in West Africa (CohMSM ANRS 12324-Expertise France),
Arch Sex Behav, vol. 49, no 1, p. 331‑345, janv. 2020. doi: 10.1007/s10508-019-01513-z.
Hedtke S. M., Kuesel A. C., Crawford K. E., Graves P. M., Boussinesq M., Lau C. L., Boakye D. A., et Grant W. N.,
Genomic Epidemiology in Filarial Nematodes: Transforming the Basis for Elimination Program Decisions,
Front Genet, vol. 10, p. 1282, janv. 2020. doi: 10.3389/fgene.2019.01282.
Pion S. D., Nana-Djeunga H., Niamsi-Emalio Y., Chesnais C. B., Deléglise H., Mackenzie C., Stolk W., Fletcher D. A., Klion A. D., Nutman T. B., Boussinesq M., et Kamgno J.,
Implications for annual retesting after a test-and-not-treat strategy for onchocerciasis elimination in areas co-endemic with Loa loa infection: an observational cohort study,
Lancet Infect Dis, vol. 20, no 1, p. 102‑109, janv. 2020. doi: 10.1016/S1473-3099(19)30554-7.
Yakhelef N., Audibert M., Ferlazzo G., Sitienei J., Wanjala S., Varaine F., Bonnet M., et Huerga H.,
Cost-effectiveness of diagnostic algorithms including lateral-flow urine lipoarabinomannan for HIV-positive patients with symptoms of tuberculosis,
PLoS ONE, vol. 15, no 1, p. e0227138, janv. 2020. doi: 10.1371/journal.pone.0227138.
Tram J., Le Baccon-Sollier P., Bolloré K., Ducos J., Mondain A.-M., Pastor P., Pageaux G.-P., Makinson A., Van de Perre P., et Tuaillon E.,
RNA testing for the diagnosis of acute hepatitis A during the 2017 outbreak in France,
J. Viral Hepat., janv. 2020. doi: 10.1111/jvh.13255.
Barraud O., Robert A., Laval L., Ruimy R., Morquin D., Boyer L., et Lamy B.,
It takes two to tango: two Aeromonas isolates combine virulence and multidrug resistance in flap infection following leech therapy,
Clin. Microbiol. Infect., janv. 2020. doi: 10.1016/j.cmi.2019.12.021.
Liégeois F., Boyer S., Eymard-Duvernay S., Carrieri P., Kouanfack C., Domyeum J., Maradan G., Ducos J., Mpoudi-Ngolé E., Spire B., Delaporte E., Kuaban C., Vidal L., Laurent C., et EVOLCAM study group,
Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM),
BMC Infect. Dis., vol. 20, no 1, p. 49, janv. 2020. doi: 10.1186/s12879-020-4784-7.
Poizot-Martin I., Obry-Roguet V., Duvivier C., Lions C., Huleux T., Jacomet C., Ferry T., Cheret A., Allavena C., Bani-Sadr F., Palich R., Cabié A., Fresard A., Pugliese P., Delobel P., Lamaury I., Hustache-Mathieu L., Brégigeon S., Makinson A., Rey D., et Dat’AIDS study group,
Kaposi sarcoma among people living with HIV in the French DAT’AIDS cohort between 2010 and 2015,
J Eur Acad Dermatol Venereol, janv. 2020. doi: 10.1111/jdv.16204.
Navarro M., Camprubí D., Requena-Méndez A., Buonfrate D., Giorli G., Kamgno J., Gardon J., Boussinesq M., Muñoz J., et Krolewiecki A.,
Safety of high-dose ivermectin: a systematic review and meta-analysis,
J. Antimicrob. Chemother., janv. 2020. doi: 10.1093/jac/dkz524.
Atwine D., Baudin E., Gelé T., Muyindike W., Mworozi K., Kyohairwe R., Kananura K., Orikiriza P., Nyehangane D., K T Nanjebe D., Furlan V., Verstuyft C., Barrail-Tran A., Taburet A.-M., Bonnet M., et ANRS 12292 Rifavirenz study group,
Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial,
J. Antimicrob. Chemother., janv. 2020. doi: 10.1093/jac/dkz557.
Lienhardt C., Nunn A., Chaisson R., Vernon A. A., Zignol M., Nahid P., Delaporte E., et Kasaeva T.,
Advances in clinical trial design: Weaving tomorrow’s TB treatments,
PLoS Med., vol. 17, no 2, p. e1003059, févr. 2020. doi: 10.1371/journal.pmed.1003059.
Bonnet M.,
Xpert MTB/RIF Ultra: what is the real impact?,
Lancet Respir Med, févr. 2020. doi: 10.1016/S2213-2600(20)30050-3.
Ayouba A. et Peeters M.,
Reply to Zhang et al,
J. Infect. Dis., févr. 2020. doi: 10.1093/infdis/jiaa041.
Coulaud P.-J., Sagaon-Teyssier L., Mimi M., Maradan G., Mora M., Bourrelly M., Dembélé Keita B., Keita A. A., Anoma C., Yoro S.-A. B., Dah E. T. T., Coulibaly C., Mensah E., Agbomadji S., Palvadeau P., Bernier A., Rojas Castro D., Couderc C., Laurent C., Spire B., et CohMSM Study Group,
Changes in risky sexual behaviours among West African MSM enrolled in a quarterly HIV testing and counselling prevention programme (CohMSM ANRS 12324 – Expertise France),
Sex Transm Infect, vol. 96, no 2, p. 115‑120, mars 2020. doi: 10.1136/sextrans-2018-053892.
for the 2-Lady Group, Boyer S., Nishimwe M. L., Sagaon-Teyssier L., March L., Koulla-Shiro S., Bousmah M.-Q., Toby R., Mpoudi-Etame M. P., Ngom Gueye N. F., Sawadogo A., Kouanfack C., Ciaffi L., Spire B., et Delaporte E.,
Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa,
PharmacoEconomics Open, vol. 4, no 1, p. 45‑60, mars 2020. doi: 10.1007/s41669-019-0157-9.
Sams K., Desclaux A., et Sow S.,
« They’ll inject you and you’ll die »: from medication non-compliance to acceptance in Guinea’s Ebola treatment units,
Anthropol Med, vol. 27, no 1, p. 1‑16, mars 2020. doi: 10.1080/13648470.2019.1615749.
Tuaillon E., Kania D., Pisoni A., Bollore K., Taieb F., Ontsira Ngoyi E. N., Schaub R., Plantier J.-C., Makinson A., et Van de Perre P.,
Dried Blood Spot Tests for the Diagnosis and Therapeutic Monitoring of HIV and Viral Hepatitis B and C,
Front Microbiol, vol. 11, p. 373, mars 2020. doi: 10.3389/fmicb.2020.00373.
Frange P., Tubiana R., Sibiude J., Canestri A., Arvieux C., Brunet-Cartier C., Cotte L., Reynes J., Mandelbrot L., Warszawski J., Le Chenadec J., et ANRS EPF CO1/CO11 Study Group
Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?,
J. Antimicrob. Chemother., mars 2020. doi: 10.1093/jac/dkaa017.
Martinez L., Cords O., Horsburgh C. R., Andrews J. R., et Pediatric TB Contact Studies Consortium,
The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis,
Lancet, vol. 395, no 10228, p. 973‑984, mars 2020. doi: 10.1016/S0140-6736(20)30166-5.
Etard J.-F., Vanhems P., Atlani-Duault L., et Ecochard R.,
Potential lethal outbreak of coronavirus disease (COVID-19) among the elderly in retirement homes and long-term facilities, France, March 2020,
Euro Surveill., vol. 25, no 15, avr. 2020. doi: 10.2807/1560-7917.ES.2020.25.15.2000448.
De Baetselier I, Vuylsteke B, Yaya I, Dagnra A, Diandé S, Mensah E, Dah E, Anoma C, Koné A, Fayé-Ketté H, Yeo A, Dembélé Keita B, Laurent C, Crucitti T: CohMSM-PrEP pooling study group. To pool or not to pool samples for sexually transmitted infections detection in men who have sex with men? An evaluation of a new pooling method using the GeneXpert instrument in West Africa. Sex Transm Dis 2020, 47(8):556-561. doi: 10.1097/OLQ.0000000000001191.
Boussinesq M., Enyong P., Chounna-Ndongmo P., Njouendou A.-J., Pion S. D., Rech A., Roberge C., Gaudriault G., et Wanji S.,
Effects of an injectable long-acting formulation of ivermectin on Onchocerca ochengi in zebu cattle,
Parasite, vol. 27, p. 36, mai 2020. doi: 10.1051/parasite/2020036.
Campillo J. T., Chesnais C. B., Pion S. D. S., Gardon J., Kamgno J., et Boussinesq M.,
Individuals living in an onchocerciasis focus and treated three-monthly with ivermectin develop fewer new onchocercal nodules than individuals treated annually,
Parasit Vectors, vol. 13, no 1, p. 258, mai 2020. doi: 10.1186/s13071-020-04126-x.
Edoul G., Chia J. E., Vidal N., Guichet E., Montavon C., Delaporte E., Mpoudi Ngole E., Ayouba A., et Peeters M.,
High HIV burden and recent transmission chains in rural forest areas in southern Cameroon, where ancestors of HIV-1 have been identified in ape populations,
Infect. Genet. Evol., vol. 84, p. 104358, mai 2020. doi: 10.1016/j.meegid.2020.104358.
Lavole A., Greillier L., Mazières J., Monnet I., Kiakouama-Maleka L., Quantin X., Spano J. P., Herve L., Fraisse P., Janicot H., Audigier-Valette C., Langlais A., Morin F., Makinson A., Cadranel J., et Written on behalf of the French Cooperative Thoracic Intergroup (IFCT),
First-Line Carboplatin Plus Pemetrexed with Pemetrexed Maintenance in HIV+ Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: The Phase II IFCT-1001 CHIVA Trial,
Eur. Respir. J., mai 2020. doi: 10.1183/13993003.02066-2019.
Gobbi F., Buonfrate D., Boussinesq M., Chesnais C., Pion S., Silva R., Moro L., Rodari P., Tamarozzi F., Biamonte M., et Bisoffi Z.,
Performance of two serodiagnostic tests for loiasis in a Non-Endemic area,
PLoS Negl Trop Dis, vol. 14, no 5, p. e0008187, mai 2020. doi: 10.1371/journal.pntd.0008187.
Chesnais C. B., Bizet C., Campillo J. T., Njamnshi W. Y., Bopda J., Nwane P., Pion S. D., Njamnshi A. K., et Boussinesq M.,
A Second Population-Based Cohort Study in Cameroon Confirms the Temporal Relationship Between Onchocerciasis and Epilepsy,
Open Forum Infect Dis, vol. 7, no 6, p. ofaa206, juin 2020. doi: 10.1093/ofid/ofaa206.
Kamgno J., Tchatchueng-Mbougua J. B., Nana-Djeunga H. C., Esso L., Zouré H. G., Mackenzie C. D., et Boussinesq M.,
Community-based door to door census of suspected people living with epilepsy: empowering community drug distributors to improve the provision of care to rural communities in Cameroon,
BMC Public Health, vol. 20, no 1, p. 871, juin 2020. doi: 10.1186/s12889-020-08997-8.
Cogliati M., Roger F., Meyer W., Robert V., et Bertout S.,
New multilocus sequence typing primers to enable genotyping of AD hybrids within the Cryptococcus neoformans species complex,
Med. Mycol., juin 2020. doi: 10.1093/mmy/myaa047.
Gaillard C. M., Pion S. D., Hamou H., Sirima C., Bizet C., Lemarcis T., Rodrigues J., Esteban A., Peeters M., Mpoudi Ngole E., Mombo I., Liégeois F., Martin C., Boussinesq M., et Locatelli S.,
Detection of DNA of filariae closely related to Mansonella perstans in faecal samples from wild non-human primates from Cameroon and Gabon,
Parasit Vectors, vol. 13, no 1, p. 313, juin 2020. doi: 10.1186/s13071-020-04184-1.
Blanc F.-X., Badje A. D., Bonnet M., Gabillard D., Messou E., Muzoora C., Samreth S., Nguyen B. D., Borand L., Domergue A., Rapoud D., Natukunda N., Thai S., Juchet S., Eholié S. P., Lawn S. D., Domoua S. K., Anglaret X., Laureillard D., et STATIS ANRS 12290 Trial Team,
Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults,
N. Engl. J. Med., vol. 382, no 25, p. 2397‑2410, juin 2020. doi: 10.1056/NEJMoa1910708.
Pion S. D. et Chesnais C. B.,
Uncovering the burden of loiasis: first estimates from Gabon,
Lancet Infect Dis, juin 2020. doi: 10.1016/S1473-3099(20)30324-8.
Pion S. D. S., Chesnais C. B., Awaca-Uvon N. P., Vlaminck J., Abdou A., Kunyu-Shako B., Kuyangisa Simuna G., Tambwe J.-P., Weil G. J., et Boussinesq M.,
The impact of four years of semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: A community-based study in the Democratic Republic of the Congo,
PLoS Negl Trop Dis, vol. 14, no 6, p. e0008322, juin 2020. doi: 10.1371/journal.pntd.0008322.
Clark E., Guilpain P., Filip I. L., Pansu N., Le Bihan C., Cartron G., Tchernonog E., Roubille C., Morquin D., Makinson A., Tuaillon E., et Le Moing V.,
Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery,
Br. J. Haematol., juin 2020. doi: 10.1111/bjh.16981.
Tchiakpe E., Keke R. K., Vidal N., Ahoussinou C., Sekpe O., Dagba H. G., Gbaguidi E., Tonoukouen C., Afangnihoun A., Bachabi M., Gangbo F. A., Diop-Ndiaye H., et Toure-Kane C.,
Moderate rate of transmitted resistance mutations to antiretrovirals and genetic diversity in newly HIV-1 patients diagnosed in Benin,
BMC Research Notes, vol. 13, no 1, p. 314, juill. 2020. doi: 10.1186/s13104-020-05151-w.
Eubanks A, Dembélé Keita B, Anoma C, Dah TTE, Mensah E, Maradan G, Bourrelly M, Mora M, Riegel L, Rojas Castro D, Yaya I, Spire B, Laurent C, Sagaon-Teyssier L; CohMSM-PrEP Study Group. Reaching a different population of MSM in West Africa with the integration of PrEP into a comprehensive prevention package (CohMSM-PrEP ANRS 12369 – Expertise France). J Acquir Immune Defic Syndr 2020, 85(3) :292-301. doi: 10.1097/QAI.0000000000002453.
Wiedemann A., Foucat E., Hocini H., Lefebvre C., Hejblum B. P., Durand M., Krüger M., Keita A. K., Ayouba A., Mély S., Fernandez J.-C., Touré A., Fourati S., Lévy-Marchal C., Raoul H., Delaporte E., Koivogui L., Thiébaut R., Lacabaratz C., Lévy Y., et PostEboGui Study Group,
Long-lasting severe immune dysfunction in Ebola virus disease survivors,
Nat Commun, vol. 11, no 1, p. 3730, juill. 2020. doi: 10.1038/s41467-020-17489-7.
Wimba P. M., Bazeboso J.-A., Katchunga P. B., Tshilolo L., Longo-Mbenza B., Rabilloud M., Vanhems P., Iwaz J., Étard J.-F., et Écochard R.,
A dashboard for monitoring preventive measures in response to COVID-19 outbreak in the Democratic Republic of Congo,
Trop Med Health, vol. 48, p. 74, août 2020. doi: 10.1186/s41182-020-00262-3.
Ayouba A., Thaurignac G., Morquin D., Tuaillon E., Raulino R., Nkuba A., Lacroix A., Vidal N., Foulongne V., Le Moing V., Reynes J., Delaporte E., et Peeters M.,
Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV,
Journal of Clinical Virology, vol. 129, p. 104521, août 2020. doi: 10.1016/j.jcv.2020.104521.
Lacroix A., Vidal N., Keita A. K., Thaurignac G., Esteban A., De Nys H., Diallo R., Toure A., Goumou S., Soumah A. K., Povogui M., Koivogui J., Monemou J.-L., Raulino R., Nkuba A., Foulongne V., Delaporte E., Ayouba A., et Peeters M.,
Wide Diversity of Coronaviruses in Frugivorous and Insectivorous Bat Species: A Pilot Study in Guinea, West Africa,
Viruses, vol. 12, no 8, août 2020. doi: 10.3390/v12080855.
Toyé R. M., Lô G., Diop-Ndiaye H., Cissé A. M., Ndiaye A. J. S., Kébé-Fall K., Dramé A., Cohen D., Pujol F. H., Mboup S., Boye C. S., Chemin I., Laborde-Balen G., Taverne B., et Touré-Kane C.,
Prevalence and molecular characterization of hepatitis B virus infection in HIV-infected children in Senegal,
Clin Res Hepatol Gastroenterol, août 2020. doi: 10.1016/j.clinre.2020.07.007.
Villeneuve F., Cabot J.-M., Eymard-Duvernay S., Visier L., Tribout V., Perollaz C., Reynes J., et Makinson A.,
Evaluating family physicians’ willingness to prescribe PrEP,
Med Mal Infect, août 2020. doi: 10.1016/j.medmal.2020.02.003.
Campillo J. T., Awaca-Uvon N. P., Missamou F., Tambwe J.-P., Kuyangisa-Simuna G., Weil G. J., Louya F., Boussinesq M., Pion S. D. S., et Chesnais C. B.,
Results from two cohort studies in Central Africa show that clearance of Wuchereria bancrofti infection after repeated rounds of mass drug administration with albendazole alone is closely linked to individual adherence,
Clin. Infect. Dis., août 2020. doi: 10.1093/cid/ciaa1232.
Gryseels S., Mbala-Kingebeni P., Akonda I., Angoyo R., Ayouba A., Baelo P., Mukadi D. B., Bugentho E., Bushmaker T., Butel C., Calvignac-Spencer S., Delaporte E., De Smet B., Düx A., Edidi-Atani F., Fischer R., Kahandi C., Kapetshi J., Sumba S. K., Kouadio L., Bendeke A. M., Mande C., Sepolo G. M., Moudindo J., Ngole E. M., Musaba P., Mutombo P., Bass I. N., Nebesse C., Ngoy S., Kumogo S.-P. N., Seifert S. N., Tanzito J., Akaibe D., Amundala N., Ariën K. K., Gembu G.-C., Leendertz F. H., Leirs H., Mukinzi J.-C., Munster V., Muyembe-Tamfum J.-J., Peeters M., Verheyen E., et Ahuka-Mundeke S.,
Role of Wildlife in Emergence of Ebola Virus in Kaigbono (Likati), Democratic Republic of the Congo, 2017,
Emerging Infect. Dis., vol. 26, no 9, p. 2205‑2209, sept. 2020. doi: 10.3201/eid2609.191552.
Katlama C., Assoumou L., Valantin M.-A., Soulié C., Martinez E., Béniguel L., Bouchaud O., Raffi F., Molina J.-M., Fellahi S., Peytavin G., Marcelin A.-G., Kolta S., Capeau J., Gibowski S., Cardon F., Reynes J., et Costagliola D.,
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-authors’ response,
J. Antimicrob. Chemother., sept. 2020. doi: 10.1093/jac/dkaa341.
Calmy A., Tovar Sanchez T., Kouanfack C., Mpoudi-Etame M., Leroy S., Perrineau S., Lantche Wandji M., Tetsa Tata D., Omgba Bassega P., Abong Bwenda T., Varloteaux M., Tongo M., Mpoudi-Ngolé E., Montoyo A., Mercier N., LeMoing V., Peeters M., Reynes J., Delaporte E., et New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group,
Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon,
Lancet HIV, vol. 7, no 10, p. e677‑e687, oct. 2020. doi: 10.1016/S2352-3018(20)30238-1.
Lounnas M., Diack A., Nicol M. P., Eyangoh S., Wobudeya E., Marcy O., Godreuil S., et Bonnet M.,
Laboratory development of a simple stool sample processing method diagnosis of pediatric tuberculosis using Xpert Ultra,
Tuberculosis (Edinb), vol. 125, p. 102002, oct. 2020. doi: 10.1016/j.tube.2020.102002.
Etard J.-F.,
Immunity to Ebola virus: the full picture is being revealed,
Lancet Infect Dis, oct. 2020. doi: 10.1016/S1473-3099(20)30793-3.
Calmy A., Tovar Sanchez T., Kouanfack C., Mpoudi-Etame M., Leroy S., Perrineau S., Lantche Wandji M., Tetsa Tata D., Omgba Bassega P., Abong Bwenda T., Varloteaux M., Tongo M., Mpoudi-Ngolé E., Montoyo A., Mercier N., LeMoing V., Peeters M., Reynes J., Delaporte E., et New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group,
Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon,
Lancet HIV, vol. 7, no 10, p. e677‑e687, 2020. doi: 10.1016/S2352-3018(20)30238-1.
Lemarcis T., Chesnais C. B., Pion S. D. S., Boussinesq M., et Locatelli S.,
Detection of a Larva of Armillifer armillatus in a Potto (Perodicticus potto) from the Republic of the Congo,
J Parasitol, vol. 106, no 5, p. 654‑662, oct. 2020. doi: 10.1645/20-51.
Hemelaar J., Elangovan R., Yun J., Dickson-Tetteh L., Kirtley S., Gouws-Williams E., Ghys P. D., et WHO-UNAIDS Network for HIV Isolation and Characterisation,
Global and regional epidemiology of HIV-1 recombinants in 1990-2015: a systematic review and global survey,
Lancet HIV, vol. 7, no 11, p. e772‑e781, nov. 2020. doi: 10.1016/S2352-3018(20)30252-6.
Wargny M., Gourdy P., Ludwig L., Seret-Bégué D., Bourron O., Darmon P., Amadou C., Pichelin M., Potier L., Thivolet C., Gautier J.-F., Hadjadj S., Cariou B., et CORONADO investigators,
Type 1 Diabetes in People Hospitalized for COVID-19: New Insights From the CORONADO Study,
Diabetes Care, vol. 43, no 11, p. e174‑e177, 2020. doi: 10.2337/dc20-1217.
Bistoquet M., Galtier F., Marin G., Villard O., Ferreira R., Hermabessiere S., Montoya A., Jumas-Bilak E., Pageaux G.-P., Dereure O., Chanques G., Klouche K., Morquin D., Reynes J., Le Moing V., Picot M.-C., Tuaillon E., et Makinson A.,
Increased risks of SARS-CoV-2 Nosocomial Acquisition in high-risk COVID-19 units justify personal Protective Equipment: a cross sectional study,
J Hosp Infect, oct. 2020. doi: 10.1016/j.jhin.2020.10.022.
Chesnais C. B., Pion S. D., Boullé C., Gardon J., Gardon-Wendel N., Fokom-Domgue J., Kamgno J., et Boussinesq M.,
Individual risk of post-ivermectin serious adverse events in subjects infected with Loa loa,
EClinicalMedicine, vol. 28, p. 100582, oct. 2020. doi: 10.1016/j.eclinm.2020.100582.
Séverin D., Faiza B., Nadia M., Aurelie D. T., Brigitte T., Bernard G., et Alain M.,
Kaposi sarcoma in people living with HIV: a comparative study of classic and HIV-viremic and aviremic AIDS Kaposi Sarcoma,
AIDS, nov. 2020. doi: 10.1097/QAD.0000000000002744.
Bertagnolio S., Hermans L., Jordan M. R., Avila-Rios S., Iwuji C., Derache A., Delaporte E., Wensing A., Aves T., Borhan A. S. M., Leenus A., Parkin N., Doherty M., Inzaule S., et Mbuagbaw L.,
Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Therapy: A Systematic Review and Meta-analysis,
J Infect Dis, nov. 2020. doi: 10.1093/infdis/jiaa683.
Bedin A.-S., Makinson A., Picot M.-C., Mennechet F., Malergue F., Pisoni A., Nyiramigisha E., Montagnier L., Bollore K., Debiesse S., Morquin D., Bourgoin P., Veyrenche N., Renault C., Foulongne V., Bret C., Bourdin A., Le Moing V., Van de Perre P., et Tuaillon E.,
Monocyte CD169 expression as a biomarker in the early diagnosis of COVID-19,
J Infect Dis, nov. 2020. doi: 10.1093/infdis/jiaa724.
Beckert P., Sanchez-Padilla E., Merker M., Dreyer V., Kohl T. A., Utpatel C., Köser C. U., Barilar I., Ismail N., Omar S. V., Klopper M., Warren R. M., Hoffmann H., Maphalala G., Ardizzoni E., de Jong B. C., Kerschberger B., Schramm B., Andres S., Kranzer K., Maurer F. P., Bonnet M., et Niemann S.,
MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era,
Genome Med, vol. 12, no 1, p. 104, nov. 2020. doi: 10.1186/s13073-020-00793-8.
Novelli S., Lécuroux C., Goujard C., Reynes J., Villemant A., Blum L., Essat A., Avettand-Fenoël V., Launay O., Molina J.-M., Bourgeois C., et Meyer L.,
Persistence of monocyte activation under treatment in people followed since acute HIV-1 infection relative to participants at high or low risk of HIV infection,
EBioMedicine, vol. 62, p. 103129, nov. 2020. doi: 10.1016/j.ebiom.2020.103129.
Blok D. J., Kamgno J., Pion S. D., Nana-Djeunga H. C., Niamsi-Emalio Y., Chesnais C. B., Mackenzie C. D., Klion A. D., Fletcher D. A., Nutman T. B., de Vlas S. J., Boussinesq M., et Stolk W. A.,
Feasibility of onchocerciasis elimination using a « test-and-not-treat » strategy in Loa loa co-endemic areas,
Clin Infect Dis, déc. 2020. doi: 10.1093/cid/ciaa1829.
Bousmah M.-A.-Q., Nishimwe M. L., Tovar-Sanchez T., Lantche Wandji M., Mpoudi-Etame M., Maradan G., Omgba Bassega P., Varloteaux M., Montoyo A., Kouanfack C., Delaporte E., Boyer S., et New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group,
Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial),
Pharmacoeconomics, déc. 2020. doi: 10.1007/s40273-020-00987-3.